Excelsior Medical Co Ltd

Excelsior Medical Co Ltd maintains a capital structure with a debt-to-equity ratio of 0.23, indicating a relatively conservative leverage position. The company's liquidity is assessed as medium, with a current ratio of 1.67, suggesting it can cover its short-term obligations but with limited excess capacity. The company's price-to-book ratio is 1.43, and its price-to-tangible-book ratio is also 1.43, indicating that the market values the company's equity at a moderate premium to its book value.

In terms of profitability, Excelsior Medical Co Ltd reports a return on equity (ROE) of 8.77% and a return on assets (ROA) of 4.25%. These figures are below the industry median for ROE and ROA, suggesting that the company is underperforming its peers in terms of capital efficiency and asset utilization. The company's operating margin is 8.28% (calculated from operating income of 727,539,000 TWD on revenue of 8,789,236,000 TWD), which is also below the industry median for operating margin.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification increases the company's exposure to regional economic fluctuations and sector-specific risks.

Excelsior Medical Co Ltd's growth trajectory is mixed. The company's current fiscal year (FY) revenue is 8,789,236,000 TWD, and the outlook for the next FY is not provided in the available data. However, the company's free cash flow of 561,375,000 TWD indicates that it is generating positive cash from operations after capital expenditures, which could support future growth initiatives.

The company's risk profile includes a medium liquidity risk, as noted in the risk assessment, and a low dilution risk. The risk assessment also flags that the company's net cash is negative after subtracting total debt, which could impact its ability to fund operations or invest in growth without external financing. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding.

Recent events and disclosures for Excelsior Medical Co Ltd include the latest financial results, which show a revenue of 8,789,236,000 TWD. The company has not disclosed any major recent filings or transcripts that would indicate significant changes in its business strategy or financial position.